Schizophrenia

Xanomeline trospium chloride offers a new pathway in schizophrenia treatment, improving cognitive symptoms without D2 receptor-related side effects like tardive dyskinesia.

Findings suggest obstetric complications are associated with more severe psychopathological phenotypes in schizophrenia and related disorders.

A study of more than 130k with schizophrenia revealed significant variability in relapse and treatment failure rates across different antipsychotics.

Being female and having bipolar II disorder were independent risk factors for serious AEs in a new study.

These data suggest that relapse among those with schizophrenia may be common 6 months after ECT, with more than half of patients likely to experience relapse within 2 years.

HCPLive spoke with Monroe regarding muscarinic modulators, both the ones in development and xanomeline trospium chloride capsules (Cobenfy).

Findings highlight high healthcare resource utilization and costs but low psychotherapy utilization, frequent relapse, and pharmacologic therapy discontinuation.

HCPLive spoke with Maguire about the benefits of acetylcholine and muscarinic receptors for the treatment of schizophrenia.

In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.

In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.

A study reveals that individuals with schizophrenia spectrum disorders experience high rates of comorbid mental health conditions and receive minimally adequate treatment.

The FDA approves Cobenfy, the first pharmacological approach to treating schizophrenia since the 1970s.

A new study finds causal links between schizophrenia and MDD on IBS, highlighting the need for integrated care addressing both psychiatric and gastrointestinal symptoms.

A new study suggests lower cognitive functioning may be a risk factor for natural cause mortality in people with schizophrenia.

A phase 2 trial met its primary endpoint, showing NBI-1117568, the first M4 selective agonist, is effective and safe at treating adult schizophrenia.

This extended-release injectable suspension for schizophrenia and schizoaffective disorder is approved as a monotherapy and as an adjunct to mood stabilizers or antidepressants.

Schizophrenia experts discuss the stigma and misconceptions surrounding schizophrenia as well as current treatment options.

Despite often presenting to the hospital with similar non-psychiatric conditions, patients with schizophrenia often experience a more difficult care process than those without.